These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 25145599)

  • 1. Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    Clin Otolaryngol; 2015 Feb; 40(1):16-21. PubMed ID: 25145599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.
    Sheikh SI; Long FR; McCoy KS; Johnson T; Ryan-Wenger NA; Hayes D
    J Cyst Fibros; 2015 Jan; 14(1):84-9. PubMed ID: 25049054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Real-world effectiveness of ivacaftor in children with cystic fibrosis and the G551D mutation].
    Gomez-Pastrana D; Nwokoro C; McLean M; Brown S; Christiansen N; Pao CS
    An Pediatr (Engl Ed); 2019 Mar; 90(3):148-156. PubMed ID: 30093322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
    Heltshe SL; Mayer-Hamblett N; Burns JL; Khan U; Baines A; Ramsey BW; Rowe SM;
    Clin Infect Dis; 2015 Mar; 60(5):703-12. PubMed ID: 25425629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.
    De Boeck K; Munck A; Walker S; Faro A; Hiatt P; Gilmartin G; Higgins M
    J Cyst Fibros; 2014 Dec; 13(6):674-80. PubMed ID: 25266159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.
    Vreede CL; Berkhout MC; Sprij AJ; Fokkens WJ; Heijerman HG
    J Cyst Fibros; 2015 May; 14(3):412-3. PubMed ID: 25169789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CFTR-dependent chloride efflux in cystic fibrosis mononuclear cells is increased by ivacaftor therapy.
    Guerra L; D'Oria S; Favia M; Castellani S; Santostasi T; Polizzi AM; Mariggiò MA; Gallo C; Casavola V; Montemurro P; Leonetti G; Manca A; Conese M
    Pediatr Pulmonol; 2017 Jul; 52(7):900-908. PubMed ID: 28445004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivacaftor improves rhinologic, psychologic, and sleep-related quality of life in G551D cystic fibrosis patients.
    McCormick J; Cho DY; Lampkin B; Richman J; Hathorne H; Rowe SM; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Mar; 9(3):292-297. PubMed ID: 30472785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ivacaftor as salvage therapy in a patient with cystic fibrosis genotype F508del/R117H/IVS8-5T.
    Carter S; Kelly S; Caples E; Grogan B; Doyle J; Gallagher CG; McKone EF
    J Cyst Fibros; 2015 Jul; 14(4):e4-5. PubMed ID: 25698453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation.
    Seliger VI; Rodman D; Van Goor F; Schmelz A; Mueller P
    J Cyst Fibros; 2013 Dec; 12(6):706-13. PubMed ID: 23628510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.
    Rowe SM; Heltshe SL; Gonska T; Donaldson SH; Borowitz D; Gelfond D; Sagel SD; Khan U; Mayer-Hamblett N; Van Dalfsen JM; Joseloff E; Ramsey BW;
    Am J Respir Crit Care Med; 2014 Jul; 190(2):175-84. PubMed ID: 24927234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ivacaftor in patients with cystic fibrosis who have an Arg117His-CFTR mutation: a double-blind, randomised controlled trial.
    Moss RB; Flume PA; Elborn JS; Cooke J; Rowe SM; McColley SA; Rubenstein RC; Higgins M;
    Lancet Respir Med; 2015 Jul; 3(7):524-33. PubMed ID: 26070913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
    Guimbellot JS; Baines A; Paynter A; Heltshe SL; VanDalfsen J; Jain M; Rowe SM; Sagel SD;
    J Cyst Fibros; 2021 Mar; 20(2):213-219. PubMed ID: 33249004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
    Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
    Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
    Salvatore D; Carnovale V; Iacotucci P; Braggion C; Castellani C; Cimino G; Colangelo C; Francalanci M; Leonetti G; Lucidi V; Manca A; Vitullo P; Ferrara N
    Pediatr Pulmonol; 2019 Sep; 54(9):1398-1403. PubMed ID: 31237430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
    Harris JK; Wagner BD; Zemanick ET; Robertson CE; Stevens MJ; Heltshe SL; Rowe SM; Sagel SD
    Ann Am Thorac Soc; 2020 Feb; 17(2):212-220. PubMed ID: 31604026
    [No Abstract]   [Full Text] [Related]  

  • 20. Nutritional Status Improved in Cystic Fibrosis Patients with the G551D Mutation After Treatment with Ivacaftor.
    Borowitz D; Lubarsky B; Wilschanski M; Munck A; Gelfond D; Bodewes F; Schwarzenberg SJ
    Dig Dis Sci; 2016 Jan; 61(1):198-207. PubMed ID: 26250833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.